Media Summary: Listen in as the Global Head of Enterprise Strategy and Architecture at ... compliance, and trust standards essential to a global It starts with hope. Our mission, To one day find a cure for cancer. Join us in our ambition as we empower and inspire the next ...

How Astrazeneca Is Leading Pharma - Detailed Analysis & Overview

Listen in as the Global Head of Enterprise Strategy and Architecture at ... compliance, and trust standards essential to a global It starts with hope. Our mission, To one day find a cure for cancer. Join us in our ambition as we empower and inspire the next ... Our BPD team comes together with a love of science, thriving on collaboration, discussion and making the world a better place ... Cell therapy is a promising, rapidly advancing field with the potential to transform treatment across disease areas with significant ... In this episode of IDEA Collider, we sit down with Susan Galbraith from

Photo Gallery

How AstraZeneca is Leading Pharma Data and AI Strategy
How AstraZeneca is Defining a New Era of Agentic Transformation
Alexion, AstraZeneca Rare Disease: Who We Are
Big pharma in focus: What’s driving AstraZeneca and GSK right now
AstraZeneca is leading a revolution to redefine cancer care
Meet the Bio-Pharmaceutical Development Team: Life at AstraZeneca
Pharma industry has a trust issue, AstraZeneca CEO says | CNBC Conversation
Podcast: Episode 100 - A discussion on AstraZeneca PLC (NASDAQ: AZN) for FY 2024 (Audio Only)
AstraZeneca   CSPC Deal
Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot
Inside AstraZeneca Modern Pharmaceutical Production Plant | Modern Factory
Harnessing the Power of Cell Therapy in Medicine
View Detailed Profile
How AstraZeneca is Leading Pharma Data and AI Strategy

How AstraZeneca is Leading Pharma Data and AI Strategy

Listen in as the Global Head of Enterprise Strategy and Architecture at

How AstraZeneca is Defining a New Era of Agentic Transformation

How AstraZeneca is Defining a New Era of Agentic Transformation

... compliance, and trust standards essential to a global

Alexion, AstraZeneca Rare Disease: Who We Are

Alexion, AstraZeneca Rare Disease: Who We Are

At Alexion,

Big pharma in focus: What’s driving AstraZeneca and GSK right now

Big pharma in focus: What’s driving AstraZeneca and GSK right now

AstraZeneca

AstraZeneca is leading a revolution to redefine cancer care

AstraZeneca is leading a revolution to redefine cancer care

It starts with hope. Our mission, To one day find a cure for cancer. Join us in our ambition as we empower and inspire the next ...

Meet the Bio-Pharmaceutical Development Team: Life at AstraZeneca

Meet the Bio-Pharmaceutical Development Team: Life at AstraZeneca

Our BPD team comes together with a love of science, thriving on collaboration, discussion and making the world a better place ...

Pharma industry has a trust issue, AstraZeneca CEO says | CNBC Conversation

Pharma industry has a trust issue, AstraZeneca CEO says | CNBC Conversation

Pascal Soriot, CEO of

Podcast: Episode 100 - A discussion on AstraZeneca PLC (NASDAQ: AZN) for FY 2024 (Audio Only)

Podcast: Episode 100 - A discussion on AstraZeneca PLC (NASDAQ: AZN) for FY 2024 (Audio Only)

In this podcast, we discuss

AstraZeneca   CSPC Deal

AstraZeneca CSPC Deal

AstraZeneca

Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot

Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot

Pascal Soriot, CEO of British

Inside AstraZeneca Modern Pharmaceutical Production Plant | Modern Factory

Inside AstraZeneca Modern Pharmaceutical Production Plant | Modern Factory

Step inside

Harnessing the Power of Cell Therapy in Medicine

Harnessing the Power of Cell Therapy in Medicine

Cell therapy is a promising, rapidly advancing field with the potential to transform treatment across disease areas with significant ...

Creating Breakthroughs in Oncology: A Conversation with Susan Galbraith of AstraZeneca

Creating Breakthroughs in Oncology: A Conversation with Susan Galbraith of AstraZeneca

In this episode of IDEA Collider, we sit down with Susan Galbraith from